

**Francesco Zaja**

* Associate Professor, Department of Medical, Surgical and Health Sciences, University of Trieste, Italy
* Director Dpt. Hematology, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste

**Affiliations to scientific societies**

* Member of the Italian Society of Hematology (SIE)
* Member of the European Hematological Asscoiation (EHA)
* Secretary of the GIMEMA Working Group on Anemia and Thrombocytopenia
* Founding Member of European Research Consortium Immune Thrombocytopenia (ERCI)

**Publications on ITP**

1. Zaja F, Iacona I, Masolini P, et al. *B-cell depletion with Rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.* Haematologica. 2002;87:189-195.
2. Zaja F, Vianelli N, Sperotto A, et al*. B-cell compartment as selective target for the treatment of immune thrombocytopenias.* Haematologica. 2003;88:538-46.
3. Zaja F, Vianelli N, Sperotto A, et al. *Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases.* Leuk Lymphoma. 2003;44:1951-5.
4. Zaja F, De Vita S, Vianelli N, et al*. The new therapeutic indications for rituximab.* Haematologica. 2003, 88 (suppl.10): 20-22.
5. [Zaja F](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Zaja+F%22%5BAuthor%5D), [Vianelli N](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Vianelli+N%22%5BAuthor%5D), [Battista M](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Battista+M%22%5BAuthor%5D), et al. *Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia.* Exp Hematol. 2006;34:571-2.
6. [Zaja F](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Zaja%20F%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Battista ML](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Battista%20ML%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Pirrotta MT](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pirrotta%20MT%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), et al*. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura*. Haematologica. 2008;93:930-3.
7. [Toffoletti E](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Toffoletti%20E%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Zaja F](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Zaja%20F%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Chiarvesio A](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chiarvesio%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), et al. *No evidences for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy.* Haematologica. 2008;93:795-6.
8. [Medeot M](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Medeot%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Zaja F](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Zaja%20F%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Vianelli N](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Vianelli%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), et al. *Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results*. Eur J Haematol. 2008;81:165-9.
9. Michel M, Chanet V, Dechartres A, Zaja F, et al. *The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases*. Blood. 2009;114:3167-72.
10. Zaja F, Baccarani M, Mazza P, et al. *Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia*. Blood. 2010;115:2755-62.
11. Zaja F, Vianelli N, Volpetti S, et al*. Low dose rituximab in adult patients with primary immune thrombocytopenia.* Eur J Haematol. 2010;85:329-334.
12. Zaja F, Geromin A, Patriarca F, Puglisi S, Cerno M, Sperotto A, Battista ML, Isola M, Fanin R. [*Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant.*](http://www.ncbi.nlm.nih.gov/pubmed/21830231) Am J Hematol. 2011;86:790-2.
13. Zaja F, Marin L, Chiozzotto M, Puglisi S, Volpetti S, Fanin R. [*Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab*.](http://www.ncbi.nlm.nih.gov/pubmed/22190262) Am J Hematol. 2012;87:321-3.
14. Zaja F, Volpetti S, Chiozzotto M, et al. *Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.* Am J Hematol. 2012; 87:886–889, 2012.
15. Ruggeri M, Tosetto A, Palandri F, Zaja F, et al. *Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors*. J Thromb Haemost. 2014;12:1266-73.
16. Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R. [*Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.*](https://www.ncbi.nlm.nih.gov/pubmed/26910388) Am J Hematol. 2016;91:E293-5.
17. Boggio E, Gigliotti CL, Rossi D, Zaja F*.* [*Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia.*](https://www.ncbi.nlm.nih.gov/pubmed/27391055) Br J Haematol. 2017;176:258-267.
18. Marangon M, Vianelli N, Palandri F, Zaja F*.* [*Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response.*](https://www.ncbi.nlm.nih.gov/pubmed/27981682) Eur J Haematol. 2017;98:371-377.
19. Bussel J, Arnold DM, Grossbard E, Zaja F, et al*.* [*Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.*](https://www.ncbi.nlm.nih.gov/pubmed/29696684)Am J Hematol. 2018;93:921-930.
20. Cantoni S, Carpenedo M, Mazzucconi MG, Zaja F, et al. [*Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers*.](https://www.ncbi.nlm.nih.gov/pubmed/28983953) Am J Hematol. 2018;93:58-64.
21. Lucchini E, Fanin R, Cooper N, Zaja F*.* [*Management of immune thrombocytopenia in elderly patients.*](https://www.ncbi.nlm.nih.gov/pubmed/30274902) Eur J Intern Med. 2018;58:70-76.
22. Lucchini E, Zaja F, Bussel J. [*Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?*](https://pubmed.ncbi.nlm.nih.gov/31126963/) Haematologica. 2019 Jun;104(6):1124-1135.
23. Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ. *Updated international consensus report on the investigation and management of primary immune thrombocytopenia*. Blood Adv. 2019 Nov 26;3(22):3780-3817.
24. Zaja F, Carpenedo M, Baratè C, et al. *Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations*. Blood Rev 2020;41:100647.

**Main oral presentations on ITP in international Meetings**

* 49° Meeting of the American Society of Hematology (ASH), Atlanta 2007.
* Plenary Session (abstract #1) at the 50° Meeting of the American Society of Hematology (ASH), San Francisco 2008.
* American Society of Clinical Oncology (ASCO), Orlando 2009.
* Meet the Expert at the Meeting of the European Hematology Association, Berlin 2009.
* Plenary Session at the Meeting of the Italian Society of Hematology (SIE), Napoli 2011.
* International Society of Hematology (ISH), Glasgow 2016.

**Study chairman in studies on ITP**

# Randomized prospective study comparing Dexamethasone and Dexamethasone plus Rituximab in the treatment of Idiopathic Thrombocytopenic Purpura (ITP) in adults. ML18542 study.

# Immune genetic characterization of ITP in adults (UNIT study).

# Eltrombopag in patients with delayed post transplant thrombocytopenia (GIMEMA ITP0511 study).

# Eltrombopag as second line therapy in adult patients with primary Immune Thrombocytopenia (ESTIT study) in an attempt to achieve long-term remission: a single arm multicenter phase II clinical and biological study (GIMEMA ITP0815 study).